BioNTech has been criticized by some campaign groups for refusing to suspend its vaccine patents and let rivals manufacture the shots as part of an effort to make them more widely available, especially in poor countries.

Join The Ecosystem

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}